SEC Info - Marinus Pharmaceuticals Inc. - ‘8-K’ for 9/22/20

SEC Info℠

Home

My Interests

Help

Please Sign In

Marinus Pharmaceuticals Inc. – ‘8-K’ for 9/22/20 – ‘EX-3.2’

On: Tuesday, 9/22/20, at 9:24am ET · For: 9/22/20 · Accession #: 1104659-20-107215 · File #: 1-36576

Previous ‘8-K’: ‘8-K’ on / for 9/14/20 · Next: ‘8-K’ on 11/10/20 for 11/9/20 · Latest: ‘8-K’ on / for 5/17/24 · 21 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/22/20  Marinus Pharmaceuticals Inc.      8-K:5,8,9   9/22/20   13:244K                                   Toppan Merrill/FA

Current Report — Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     35K 
 2: EX-3.1      Articles of Incorporation/Organization or Bylaws    HTML     11K 
 3: EX-3.2      Articles of Incorporation/Organization or Bylaws    HTML     10K 
 4: EX-99.1     Miscellaneous Exhibit                               HTML     14K 
 9: R1          Cover                                               HTML     51K 
11: XML         IDEA XML File -- Filing Summary                      XML     13K 
 8: XML         XBRL Instance -- tm2030376-3_8k_htm                  XML     16K 
10: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 6: EX-101.LAB  XBRL Labels -- mrns-20200922_lab                     XML     97K 
 7: EX-101.PRE  XBRL Presentations -- mrns-20200922_pre              XML     64K 
 5: EX-101.SCH  XBRL Schema -- mrns-20200922                         XSD     13K 
12: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    34K 
13: ZIP         XBRL Zipped Folder -- 0001104659-20-107215-xbrl      Zip     20K

‘EX-3.2’ — Articles of Incorporation/Organization or Bylaws

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Exhibit 3.2

Certificate of Amendment
of
FOURTH Amended and Restated Certificate of Incorporation
of
marinus pharmAceuticals, Inc.

Marinus Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows:

1. The name of the Corporation is Marinus Pharmaceuticals, Inc.

2. Article 4, Section A of the Fourth Amended and Restated Certificate of Incorporation of the Corporation, as amended to date, is hereby amended by replacing the first paragraph thereof with the following:

A. Classes of Stock. The aggregate number of shares of stock that the Corporation shall have the authority to issue is 175,000,000, of which 150,000,000 shares are Common Stock with a par value of $0.001 per share (the “Common Stock”), and 25,000,000 shares are Preferred Stock with a par value of $0.001 per share (the “Preferred Stock”).

3. This Certificate of Amendment has been duly adopted by the Board of Directors and stockholders of the Corporation in accordance with Section 242 of the General Corporation Law of the State of Delaware.

4. This Certificate of Amendment shall become effective as of 5:05 p.m., Eastern Time on September 22, 2020.

[Signature page follows]

IN WITNESS WHEREOF, the Corporation has caused its duly authorized officer to execute this Certificate of Amendment on this 21^stday of September, 2020.

	MARINUS PHARMACEUTICALS, INC.

	By:	/s/ *Scott Braunstein*
	Name:	Scott Braunstein
	Title:	Chief Executive Officer

Dates Referenced Herein

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	9/22/20	None on these Dates
		List all Filings

21 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/08/24  Marinus Pharmaceuticals, Inc.     10-Q        3/31/24   68:6.5M                                   Toppan Merrill Bridge/FA
 3/05/24  Marinus Pharmaceuticals, Inc.     10-K       12/31/23   79:10M                                    Toppan Merrill Bridge/FA
11/07/23  Marinus Pharmaceuticals, Inc.     10-Q        9/30/23   65:7.3M                                   Toppan Merrill Bridge/FA
 8/10/23  Marinus Pharmaceuticals, Inc.     10-Q        6/30/23   62:6.6M                                   Toppan Merrill Bridge/FA
 6/29/23  Marinus Pharmaceuticals, Inc.     S-8         6/29/23    4:221K                                   Toppan Merrill Bridge/FA
 5/11/23  Marinus Pharmaceuticals, Inc.     10-Q        3/31/23   62:6.1M                                   Toppan Merrill Bridge/FA
 3/31/23  Marinus Pharmaceuticals, Inc.     S-3                    8:1.6M                                   Toppan Merrill/FA
 3/09/23  Marinus Pharmaceuticals, Inc.     10-K       12/31/22   73:10M                                    Toppan Merrill Bridge/FA
11/07/22  Marinus Pharmaceuticals, Inc.     10-Q        9/30/22   62:8.2M                                   Toppan Merrill Bridge/FA
 8/11/22  Marinus Pharmaceuticals, Inc.     10-Q        6/30/22   50:5.1M                                   Toppan Merrill Bridge/FA
 6/28/22  Marinus Pharmaceuticals, Inc.     S-8         6/28/22    4:131K                                   Toppan Merrill/FA
 5/12/22  Marinus Pharmaceuticals, Inc.     10-Q        3/31/22   49:4.7M                                   Toppan Merrill Bridge/FA
 3/24/22  Marinus Pharmaceuticals, Inc.     10-K       12/31/21   71:8.5M                                   Toppan Merrill Bridge/FA
11/09/21  Marinus Pharmaceuticals, Inc.     10-Q        9/30/21   57:7.3M                                   Toppan Merrill Bridge/FA
 8/10/21  Marinus Pharmaceuticals, Inc.     10-Q        6/30/21   46:4.9M                                   Toppan Merrill Bridge/FA
 8/10/21  Marinus Pharmaceuticals, Inc.     S-8         8/10/21    5:200K                                   Toppan Merrill/FA
 5/17/21  Marinus Pharmaceuticals, Inc.     10-Q        3/31/21   43:6.3M                                   Toppan Merrill Bridge/FA
 3/09/21  Marinus Pharmaceuticals, Inc.     10-K       12/31/20   65:7.6M                                   Toppan Merrill Bridge/FA
12/09/20  Marinus Pharmaceuticals, Inc.     424B5                  1:565K                                   Toppan Merrill/FA
12/07/20  Marinus Pharmaceuticals, Inc.     424B5                  1:562K                                   Toppan Merrill/FA
11/09/20  Marinus Pharmaceuticals, Inc.     10-Q        9/30/20   44:6.7M                                   Toppan Merrill Bridge/FA

↑Top

Filing Submission 0001104659-20-107215 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)